There is increasing evidence linking IL-6 to endothelial dysfunction and vascular hypertrophy, as well as fibrosis, including SSc [36, 37]; however, the contribution of other IL-6 family members to these pathological processes, especially the activation of ECs, remains relatively understudied. Here, IL6 is linked to cardiac hypertrophy.